MetaCap

Alkermes (ALKS) vs Protagonist Therapeutics (PTGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alkermes (ALKS) has outperformed Protagonist Therapeutics (PTGX) over the past year, gaining 57.1% versus a gain of 42.2%. Over five years, PTGX leads with a +265.0% price change compared with +100.0% for ALKS. Protagonist Therapeutics is the larger company by market cap ($7.92 billion vs $7.55 billion), about 1.0 times the size, while Alkermes is growing revenue faster (-5.2% vs -89.4%).

On valuation, Alkermes trades at a lower forward P/E (33.2x vs 348.8x for Protagonist Therapeutics). Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus -282.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALKS+57.08%PTGX+42.15%
+98%+43%-12%
Nov 21, 20251 yearNov 20, 2026
ALKS+93.37%PTGX+246.56%
+364%+132%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALKS versus PTGX key metrics
MetricALKSPTGX
Share price$44.94$121.40
Market cap$7.55B$7.92B
1-day change-2.69%-2.11%
YTD return+60.61%+39.00%
1-year return+57.08%+42.15%
5-year return+100.00%+265.00%
P/E ratio (TTM)—25.67
Forward P/E33.21348.79
EPS (TTM)$-0.01$4.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.48B$46.02M
Revenue growth (YoY)-5.25%-89.41%
Net income (latest FY)$241.66M$-130.15M
Gross margin86.69%—
Operating margin17.21%-343.63%
Net margin16.37%-282.83%
52-week high$55.67$160.81
52-week low$27.00$77.00
Distance from 52-week high-19.27%-24.51%
Analyst consensusbuystrong_buy
Avg. price target upside+28.48%+50.21%
Average volume1.90M668.45K
Shares outstanding168.04M65.27M
Employees2,050149
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALKS has outperformed PTGX by 14.9 percentage points over the past year.
  • Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
  • Alkermes grew revenue faster in its latest fiscal year (-5.25% vs -89.41%).

About Alkermes

ALKS stock →

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees

About Protagonist Therapeutics

PTGX stock →

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees

ALKS vs PTGX FAQ

Which is bigger, Alkermes or Protagonist Therapeutics?

Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $7.92B compared with $7.55B for Alkermes (ALKS).

Which stock has performed better over the past year, ALKS or PTGX?

ALKS returned +57.08% over the past 12 months, compared with +42.15% for PTGX (price return, excluding dividends). Past performance does not predict future results.

Are Alkermes and Protagonist Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons